GO:0014074 response to purine-containing compound: Cellular Stress Response, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0014074 (response to purine-containing compound) describes any process by which a cell or organism changes its state or activity in response to a purine-containing compound stimulus.
• Purine-containing compounds include ATP, GTP, adenosine, inosine, and synthetic purine analogs that can trigger metabolic, transcriptional, and signaling changes.
• The response is highly relevant to cancer, gout, and neurodegenerative disease, where purine metabolism and signaling are frequently dysregulated.
• Key genes involved include adenosine receptors (ADORA1, ADORA2A, ADORA2B, ADORA3), purinergic receptors (P2RX7, P2RY1), and purine-metabolizing enzymes (ADA, AMPD1, XDH, HPRT1).
• Experimental models for studying this response include CRISPR knockout, point mutation, knock-in, and overexpression cell lines, combined with transcriptomics, proteomics, and functional assays.
• EDITGENE provides end-to-end CRISPR services to dissect the causal roles of genes in the response to purine-containing compounds.
Description
The Gene Ontology term GO:0014074, response to purine-containing compound, defines any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a purine-containing compound stimulus. Purine-containing compounds encompass a wide range of biologically active molecules, including adenosine triphosphate (ATP), guanosine triphosphate (GTP), adenosine, inosine, and various synthetic purine analogs. These molecules act as energy carriers, signaling molecules, and metabolic intermediates, and their dysregulation is associated with numerous pathological conditions. Understanding how cells respond to purine-containing compounds is critical for researchers in cancer biology, immunology, neurobiology, and metabolic disease. For example, extracellular ATP and adenosine are potent modulators of immune responses and tumor microenvironment signaling. In gout, monosodium urate crystals trigger inflammation through purinergic signaling, and network pharmacology studies have identified purine-related pathways as key therapeutic targets. In Alzheimer's disease, glutamine metabolism-associated gene biomarkers, which intersect with purine metabolism, have been revealed by integrative bioinformatics and machine learning. This article provides a research-grade overview of GO:0014074, covering its definition, biological significance, key genes, regulatory mechanisms, disease associations, and state-of-the-art methods for experimental investigation. All factual statements are supported by peer-reviewed literature [1-5].
response to purine-containing compound At A Glance
| GO ID | GO:0014074 |
|---|---|
| GO term | response to purine-containing compound |
| Ontology | biological_process |
| Synonym | response to purine |
| Definition | Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a purine-containing compound stimulus. |
| Major function | Cellular and organismal adaptation to purine-containing compounds, including signaling, metabolic, and transcriptional responses. |
| Related stimuli | ATP, GTP, adenosine, inosine, purine analogs, and other purine-containing molecules. |
| Disease relevance | Cancer, gout, neurodegenerative diseases, and metabolic disorders. |
| Research methods | CRISPR knockout/knock-in, transcriptomics, proteomics, metabolomics, and functional assays. |
What Is GO:0014074?
GO:0014074, response to purine-containing compound, is a biological process term in the Gene Ontology. It is defined as any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a purine-containing compound stimulus. The synonym 'response to purine' is also used. This term captures the cellular and organismal reactions to purines such as ATP, GTP, adenosine, inosine, and their analogs, which can act as signaling molecules, metabolic regulators, or stress inducers.
Why Is response to purine-containing compound Important in Cell Biology?
GO:0014074 is important because purine-containing compounds are ubiquitous in cellular metabolism and signaling, and their dysregulation contributes to major human diseases. For instance, extracellular ATP and adenosine modulate immune responses and tumor progression, and pre-treatment DNA methylome and transcriptome profiles correlate with melanoma response to anti-PD1 immunotherapy, highlighting the role of purine-related pathways in immunotherapy outcomes. In gout, purine metabolism and inflammatory signaling are central to disease pathogenesis, and network pharmacology studies have identified purine-related targets for therapeutic intervention. In Alzheimer's disease, glutamine metabolism-associated gene biomarkers, which intersect with purine metabolism, have been identified through integrative bioinformatics and machine learning. Thus, understanding the response to purine-containing compounds is essential for developing targeted therapies and biomarkers.
• Purine-containing compounds such as ATP and adenosine are key signaling molecules in the tumor microenvironment and immune regulation.
• Dysregulated purine metabolism is a hallmark of gout and other inflammatory arthropathies.
• Purine analogs are used as chemotherapeutic agents, and cellular responses to them determine drug efficacy and resistance.
• Alzheimer's disease and other neurodegenerative conditions involve altered purine metabolism and signaling.
• Aging is associated with changes in liver proteome and acetylome, including purine-related enzymes.
• Purine-containing compounds can induce apoptosis in cancer cells, as shown for purine-containing butenolides in breast carcinoma MCF7 cells.
• Response to purine-containing compounds is relevant to immunotherapy response, as pre-treatment molecular profiles correlate with anti-PD1 outcomes.
• CRISPR-based models enable causal dissection of genes involved in purine response pathways.
• Bioinformatics and machine learning can identify purine-related biomarkers for disease diagnosis and prognosis.
• Understanding this response can guide development of purinergic receptor agonists and antagonists for therapeutic use.
What Happens During response to purine-containing compound?
Purine stimulus recognition and receptor activation
In simple terms: Cells first detect purine-containing compounds through specific receptors or sensors.
The response to purine-containing compounds begins with the recognition of the stimulus. Extracellular purines such as ATP and adenosine bind to purinergic receptors (P2X, P2Y, and adenosine receptors), while intracellular purines can be sensed by metabolic enzymes and regulatory proteins. This recognition triggers downstream signaling cascades, including calcium mobilization, cyclic AMP modulation, and kinase activation. In gout, monosodium urate crystals stimulate purinergic signaling, leading to inflammasome activation.
Signal transduction and metabolic reprogramming
In simple terms: After detection, cells activate signaling pathways and adjust their metabolism.
Following receptor activation, cells undergo signal transduction events that often involve protein kinases, phosphatases, and transcription factors. For example, adenosine receptor signaling can modulate cAMP levels and downstream PKA activity. Purine-containing compounds can also directly affect metabolic enzymes such as ribonucleotide reductase, leading to altered nucleotide pools and apoptosis in cancer cells. In Alzheimer's disease, glutamine metabolism-associated genes, which intersect with purine metabolism, are dysregulated, indicating metabolic reprogramming.
Transcriptional and epigenetic changes
In simple terms: Cells change which genes are turned on or off in response to purines.
The response to purine-containing compounds involves changes in gene expression. Pre-treatment DNA methylome and transcriptome profiles correlate with melanoma response to anti-PD1 immunotherapy, suggesting that epigenetic and transcriptional states influence how cells respond to purine-related stimuli. In aging livers, proteome and acetylome profiling revealed changes in purine-metabolizing enzymes, indicating that purine responses are linked to epigenetic modifications.
Cellular outcomes: apoptosis, proliferation, and immune modulation
In simple terms: The final result can be cell death, growth, or changes in immune activity.
Depending on the context, the response to purine-containing compounds can lead to diverse cellular outcomes. Purine-containing butenolides induce apoptosis in breast carcinoma MCF7 cells by inhibiting ribonucleotide reductase. In the tumor microenvironment, adenosine suppresses anti-tumor immunity, while ATP can promote immunogenic cell death. In gout, purine-driven inflammation causes joint damage. These outcomes highlight the pleiotropic effects of purine responses.
Key Genes Involved in GO:0014074 response to purine-containing compound
The following genes and proteins are central to the response to purine-containing compounds, based on published literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| ADORA1 | Adenosine receptor A1; inhibits adenylyl cyclase | Modulates neurotransmission and immune responses |
| ADORA2A | Adenosine receptor A2A; activates adenylyl cyclase | Target in cancer immunotherapy and neuroinflammation |
| ADORA2B | Adenosine receptor A2B; activates adenylyl cyclase | Involved in inflammation and fibrosis |
| ADORA3 | Adenosine receptor A3; inhibits adenylyl cyclase | Potential target in cancer and inflammation |
| P2RX7 | ATP-gated ion channel; activates inflammasome | Key in gout and inflammatory diseases |
| P2RY1 | G protein-coupled receptor for ATP/ADP | Regulates platelet aggregation and vascular tone |
| ADA | Adenosine deaminase; converts adenosine to inosine | Deficiency causes severe combined immunodeficiency |
| AMPD1 | AMP deaminase 1; converts AMP to IMP | Associated with metabolic myopathy |
| XDH | Xanthine dehydrogenase; produces uric acid | Target in gout and hyperuricemia |
| HPRT1 | Hypoxanthine phosphoribosyltransferase 1; purine salvage | Deficiency causes Lesch-Nyhan syndrome |
| RRM1 | Ribonucleotide reductase subunit M1; synthesizes dNTPs | Inhibited by purine analogs; target in cancer |
| RRM2 | Ribonucleotide reductase subunit M2; synthesizes dNTPs | Inhibited by purine analogs; target in cancer |
| ATIC | AICAR transformylase/IMP cyclohydrolase; purine biosynthesis | Involved in purine de novo synthesis |
| GART | Phosphoribosylglycinamide formyltransferase; purine biosynthesis | Potential biomarker in cancer |
| PAICS | Phosphoribosylaminoimidazole carboxylase; purine biosynthesis | Overexpressed in various cancers |
| ADSL | Adenylosuccinate lyase; purine biosynthesis | Deficiency causes metabolic disorders |
| NT5E | CD73; converts AMP to adenosine | Immunosuppressive in tumor microenvironment |
| ENTPD1 | CD39; converts ATP to AMP | Regulates purinergic signaling in cancer |
How Is response to purine-containing compound Regulated?
The response to purine-containing compounds is regulated at multiple levels. Extracellular purine levels are controlled by ectonucleotidases such as CD39 (ENTPD1) and CD73 (NT5E), which sequentially hydrolyze ATP to adenosine, thereby shaping the signaling milieu. Adenosine receptor expression and desensitization are regulated by transcriptional and post-translational mechanisms. Intracellular purine metabolism is feedback-regulated by enzymes such as ribonucleotide reductase and AMP deaminase. In cancer, DNA methylome and transcriptome profiles can predict response to immunotherapy, suggesting epigenetic regulation of purine-related pathways. Additionally, aging-related changes in the liver acetylome may influence purine enzyme activity.
response to purine-containing compound and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| ADORA2A | Cancer immunotherapy response; neuroinflammation | Knockout mice or cell lines; overexpression in tumor cells |
| P2RX7 | Gout; inflammatory diseases | Point mutation (loss-of-function) in macrophages |
| XDH | Gout; hyperuricemia | Knockout hepatocytes; knock-in of human variants |
| HPRT1 | Lesch-Nyhan syndrome; purine salvage deficiency | Knockout iPSCs; point mutation models |
| RRM1 | Cancer; purine analog resistance | Overexpression and knockout in cancer cell lines |
Cancer and immunotherapy response
Purine-containing compounds play a dual role in cancer. Extracellular adenosine, generated by CD39 and CD73, suppresses anti-tumor immunity, and high adenosine levels correlate with poor response to immunotherapy. Pre-treatment DNA methylome and transcriptome profiles correlate with melanoma response to anti-PD1 immunotherapy, implicating purine-related pathways in immune evasion. Conversely, purine analogs such as butenolides induce apoptosis in breast carcinoma MCF7 cells by inhibiting ribonucleotide reductase. Thus, targeting purine response pathways is a promising strategy in oncology.
Gout and inflammatory diseases
Gout is caused by deposition of monosodium urate crystals, which trigger inflammation through purinergic signaling. Network pharmacology studies of Danggui Niantong decoction in gout have revealed molecular mechanisms involving purine metabolism and inflammatory pathways. Xanthine dehydrogenase (XDH) is a key enzyme in uric acid production and is the target of allopurinol. P2RX7, an ATP-gated ion channel, activates the NLRP3 inflammasome in response to urate crystals. Therefore, the response to purine-containing compounds is central to gout pathogenesis.
Neurodegenerative diseases
Alzheimer's disease is associated with altered glutamine metabolism, which intersects with purine metabolism. Integrative bioinformatics and machine learning analyses have identified glutamine metabolism-associated gene biomarkers in Alzheimer's disease, including genes involved in purine synthesis and salvage. Adenosine receptors modulate neurotransmission and neuroinflammation, and their dysregulation has been implicated in neurodegeneration. Thus, purine response pathways are potential therapeutic targets in Alzheimer's disease and related disorders.
Aging and metabolic disorders
Aging is accompanied by changes in liver proteome and acetylome, including purine-metabolizing enzymes such as AMPD1 and XDH. These changes may contribute to age-related metabolic dysfunction. Additionally, purine metabolism disorders can lead to hyperuricemia and metabolic syndrome. Understanding how aging affects the response to purine-containing compounds may reveal interventions for age-related diseases.
From response to purine-containing compound-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does gene X mediate adenosine-induced immunosuppression? | ADORA2A knockout in melanoma cells or T cells |
| Does a point mutation in P2RX7 alter inflammasome activation? | P2RX7 point-mutation knock-in macrophages |
| Does overexpression of CD73 promote tumor growth? | CD73 (NT5E) overexpression in syngeneic tumor models |
| Does loss of HPRT1 affect purine salvage? | HPRT1 knockout iPSCs differentiated into neurons |
| Does a purine analog induce apoptosis via ribonucleotide reductase? | RRM1/RRM2 knockout or point-mutation cancer cells |
| Does aging alter purine enzyme acetylation? | Aged mouse liver models with acetylome profiling |
How to Study the response to purine-containing compound Process
| Method | What It Measures | Typical Application |
|---|---|---|
| RNA-seq | Global gene expression changes | Identify transcriptional response to purines |
| DNA methylation profiling | Epigenetic modifications | Correlate with immunotherapy response |
| Proteomics | Protein abundance and modifications | Detect purine enzyme changes in aging |
| Metabolomics | Small molecule metabolites | Quantify ATP, adenosine, uric acid |
| Apoptosis assays | Cell death | Evaluate purine analog cytotoxicity |
| Calcium flux imaging | Intracellular calcium levels | Monitor purinergic receptor activation |
| Machine learning | Biomarker discovery | Identify purine-related disease signatures |
Transcriptomics and epigenomics
RNA sequencing (RNA-seq) and DNA methylation profiling are powerful methods to study the response to purine-containing compounds. Pre-treatment DNA methylome and transcriptome profiles correlate with melanoma response to anti-PD1 immunotherapy, demonstrating the utility of these approaches. In aging studies, proteome and acetylome profiling of livers from C57BL/6J mice revealed changes in purine-metabolizing enzymes. These methods can identify global changes in gene expression and epigenetic marks following purine stimulation.
Proteomics and metabolomics
Mass spectrometry-based proteomics and metabolomics allow quantification of purine metabolites and enzyme abundance. Proteome and acetylome profiling during normal aging identified alterations in purine-related proteins. Metabolomics can measure ATP, ADP, AMP, adenosine, and uric acid levels, providing a functional readout of purine response. These techniques are essential for understanding metabolic reprogramming.
Functional assays and imaging
Functional assays such as apoptosis detection, proliferation assays, and cytokine profiling measure cellular outcomes of purine response. Purine-containing butenolides induced apoptosis in MCF7 cells, as assessed by cell viability and apoptosis assays. Live-cell imaging of calcium flux or cAMP levels can monitor immediate signaling events. These methods link molecular changes to cellular phenotypes.
Bioinformatics and machine learning
Integrative bioinformatics and machine learning analyses can identify biomarkers and pathways associated with purine response. For example, glutamine metabolism-associated gene biomarkers in Alzheimer's disease were identified using these approaches. Network pharmacology has been used to elucidate the molecular mechanism of Danggui Niantong decoction in gout, highlighting purine-related targets. These computational methods are valuable for hypothesis generation and target discovery.
How CRISPR Can Be Used to Study GO:0014074 response to purine-containing compound
Knockout
CRISPR knockout (KO) is used to delete genes involved in the response to purine-containing compounds, such as ADORA2A, P2RX7, or XDH, to assess their causal role. For example, ADORA2A KO in melanoma cells can test whether adenosine-mediated immunosuppression is abrogated. HPRT1 KO iPSCs model Lesch-Nyhan syndrome and purine salvage deficiency. KO models are essential for loss-of-function studies.
Point Mutation
CRISPR point mutation introduces specific nucleotide changes to model disease-associated variants or to dissect functional domains. For instance, point mutations in P2RX7 can mimic gain-of-function or loss-of-function variants linked to gout or inflammatory diseases. Point mutations in RRM1 can confer resistance to purine analogs, helping to understand drug resistance mechanisms. These models provide precise genetic manipulation.
Knock-in
CRISPR knock-in (KI) allows insertion of reporter tags, human disease alleles, or conditional cassettes. Tagged knock-in of ADORA2A with fluorescent proteins enables live-cell imaging of receptor trafficking. KI of human XDH variants into mouse liver can model hyperuricemia. KI models are valuable for studying gene function in a physiological context.
Overexpression
CRISPR activation (CRISPRa) or cDNA overexpression is used to upregulate genes such as NT5E (CD73) or ADORA2B to study their role in purine response. Overexpression of CD73 in tumor cells promotes adenosine generation and immunosuppression. Overexpression of RRM1 can increase ribonucleotide reductase activity and alter sensitivity to purine analogs. These gain-of-function models complement KO studies.
How EDITGENE Supports response to purine-containing compound Research
Researchers studying response to purine-containing compound-related genes often need to determine whether a candidate gene is causally involved in the cellular response to purines, and to dissect the underlying molecular mechanisms. EDITGENE provides a comprehensive suite of CRISPR-based services to accelerate this research.
Contact EDITGENE today to design your custom CRISPR model for response to purine-containing compound research.
Frequently Asked Questions About response to purine-containing compound
What is GO:0014074 response to purine-containing compound?
GO:0014074 is a Gene Ontology biological process term defined as any process that results in a change in state or activity of a cell or an organism as a result of a purine-containing compound stimulus.
What genes are involved in response to purine-containing compound?
Key genes include adenosine receptors (ADORA1, ADORA2A, ADORA2B, ADORA3), purinergic receptors (P2RX7, P2RY1), and purine-metabolizing enzymes (ADA, AMPD1, XDH, HPRT1, RRM1, RRM2).
How does adenosine trigger a cellular response?
Adenosine binds to adenosine receptors (ADORA1, ADORA2A, ADORA2B, ADORA3), modulating cAMP levels and downstream signaling, which can suppress immune responses in the tumor microenvironment.
What diseases are associated with purine response pathways?
Purine response pathways are associated with cancer, gout, Alzheimer's disease, and aging-related metabolic disorders.
How can I study response to purine-containing compounds in the lab?
Common methods include RNA-seq, DNA methylation profiling, proteomics, metabolomics, apoptosis assays, and CRISPR knockout or knock-in models.
What is the role of P2RX7 in gout?
P2RX7 is an ATP-gated ion channel that activates the NLRP3 inflammasome in response to monosodium urate crystals, contributing to gout inflammation.
Can CRISPR be used to model purine-related diseases?
Yes, CRISPR knockout, point mutation, knock-in, and overexpression models are widely used to study genes involved in purine response and related diseases.
What is the link between purine metabolism and Alzheimer's disease?
Integrative bioinformatics and machine learning analyses have identified glutamine metabolism-associated gene biomarkers, which intersect with purine metabolism, in Alzheimer's disease.
How does aging affect purine-metabolizing enzymes?
Proteome and acetylome profiling of aging mouse livers revealed changes in purine-metabolizing enzymes such as AMPD1 and XDH.
What services does EDITGENE offer for purine response research?
EDITGENE offers CRISPR knockout, point mutation, knock-in, overexpression, library screening, and bioinformatics services to study genes involved in the response to purine-containing compounds.
Conclusion
GO:0014074 response to purine-containing compound is a fundamental biological process with broad implications for cancer, gout, neurodegenerative diseases, and aging. The integration of CRISPR-based models with multi-omics and bioinformatics approaches is accelerating the discovery of causal genes and mechanisms. EDITGENE provides comprehensive services to support this research, from knockout and knock-in cell models to library screening and bioinformatics analysis.
References
- 1. Hossain SM et al.. 2025. Pre-treatment DNA methylome and transcriptome profiles correlate with melanoma response to anti-PD1 immunotherapy.. Cancer Lett 618:217638 PMID: 40089202
- 2. Liu Y et al.. 2022. The combination of molecular docking and network pharmacology reveals the molecular mechanism of Danggui Niantong decoction in treating gout.. Medicine (Baltimore) 101(47):e31535 PMID: 36451451
- 3. Liu JF et al.. 2021. [Proteome and Acetylome Profiling of Livers in C57BL/6J Male Mice during Normal Aging].. Zhongguo Yi Xue Ke Xue Yuan Xue Bao 43(5):696-705 PMID: 34728030
- 4. Xing N et al.. 2025. Alzheimer's disease: an integrative bioinformatics and machine learning analysis reveals glutamine metabolism-associated gene biomarkers.. BMC Pharmacol Toxicol 26(1):19 PMID: 39875978
- 5. Hakimelahi GH et al.. 2002. Reactions of purines-containing butenolides with L-cysteine or N-acetyl-L-cysteine as model biological nucleophiles: a potent mechanism-based inhibitor of ribonucleotide reductase caused apoptosis in breast carcinoma MCF7 cells.. Eur J Med Chem 37(3):207-17 PMID: 11900865
